| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
D. Boral Capital analyst Jason Kolbert maintains Reviva Pharmaceuticals (NASDAQ:RVPH) with a Buy and maintains $2 price target.
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Reviva Pharmaceuticals (NASDAQ:RVPH) with a Buy and lowers the ...